Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03244384 · ClinicalTrials.gov registry record · Phase 3

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

A Phase 3 study of Locally Advanced Urothelial Carcinoma and Locally Advanced Bladder Urothelial Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 3
Development phase
739
Enrollment target
20
Study locations

NCT03244384 is a Phase 3 study of Locally Advanced Urothelial Carcinoma and Locally Advanced Bladder Urothelial Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 739 participants, above the 74-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (899% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03244384, a Phase 3 study of Locally Advanced Urothelial Carcinoma and Locally Advanced Bladder Urothelial Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
739 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to grow.

Conditions Studied

Locally Advanced Urothelial Carcinoma Locally Advanced Bladder Urothelial Carcinoma Locally Advanced Ureter Urothelial Carcinoma Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma Localized Renal Pelvis and Ureter Urothelial Carcinoma Stage II Ureter Cancer AJCC v7 Stage II Renal Pelvis and Ureter Cancer AJCC v7 Stage III Renal Pelvis and Ureter Cancer AJCC v7

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • OTHER Clinical Observation
  • PROCEDURE Cystoscopy
  • PROCEDURE CT Urography

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Arizona

  • CTCA at Western Regional Medical Center - Goodyear
  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • John L McClellan Memorial Veterans Hospital - Little Rock

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Trial Details

FieldValue
Enrollment Target 739 participants
Start Date 2017-11-03
Est. Completion 2026-06-01
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03244384

The ClinicalTrials.gov registry entry for NCT03244384 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 74-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (899% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Locally Advanced Urothelial Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT03244384 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alaska, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT03244384 about?

NCT03244384 is a clinical study titled "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer". This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal anti...

What is the current status of trial NCT03244384?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 739 participants. The study started on 2017-11-03. Estimated completion is 2026-06-01.

What conditions does trial NCT03244384 study?

This clinical trial studies the following conditions: Locally Advanced Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7.

What interventions are being tested in trial NCT03244384?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Clinical Observation (OTHER), Cystoscopy (PROCEDURE), CT Urography (PROCEDURE).

Who is sponsoring clinical trial NCT03244384?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03244384 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced Urothelial Carcinoma

All registered trials for this condition

Locally Advanced Bladder Urothelial Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.